X
CRNX

Xponance’s Crinetics Pharmaceuticals CRNX Stock Holding History

Xponance’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Buy
10,324
+1,281
+14% +$47.6K ﹤0.01% 1248
2026
Q1 		$328K Buy
9,043
+1,848
+26% +$82.5K ﹤0.01% 1214
2025
Q4 		$335K Buy
7,195
+96
+1% +$4.27K ﹤0.01% 1125
2025
Q3 		$296K Buy
7,099
+98
+1% +$3.13K ﹤0.01% 1165
2025
Q2 		$201K Buy
7,001
+144
+2% +$4.45K ﹤0.01% 1330
2025
Q1 		$230K Buy
6,857
+573
+9% +$21.4K ﹤0.01% 1218
2024
Q4 		$321K Buy
6,284
+1,168
+23% +$65.3K ﹤0.01% 1105
2024
Q3 		$261K Buy
5,116
+186
+4% +$9.59K ﹤0.01% 1131
2024
Q2 		$221K Buy
+4,930
New +$228K ﹤0.01% 1150

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Xponance's CRNX Position: Q2 2026 in Review

Xponance increased its Crinetics Pharmaceuticals (CRNX) stake by 14% in Q2 2026, buying an estimated $47.6K and bringing the position to 10,324 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #1248.

Xponance first reported a position in CRNX in Q2 2024 and has held it in 9 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Xponance held 10,324 shares of Crinetics Pharmaceuticals worth $386K as of Q2 2026.
  • Xponance bought 1,281 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $47.6K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1248 holding.
  • Xponance first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.